CytoDyn Inc (OTCPK:CYDY)

$ 0.1246 -0.0024 (-1.89%) Market Cap: 151.99 Mil Enterprise Value: 159.16 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 35/100

Cytodyn Inc Company Update Call Transcript
Dec 14, 2023
Cytodyn Inc Annual Shareholders Meeting Transcript
Nov 09, 2023
Cytodyn Inc Investment Community Webcast Transcript
Jul 24, 2023
Cytodyn Inc To Provide a Company Update Transcript
Apr 11, 2023
Cytodyn Inc Investment Community Webcast Transcript
Dec 29, 2022
Cytodyn Inc To Host R&D Update-Virtual Transcript
Dec 07, 2022
Cytodyn Inc Investment Community Webcast Transcript
Oct 31, 2022
Cytodyn Inc Investment Community Webcast Transcript
Sep 28, 2022
Cytodyn Inc Investment Community Webcast Transcript
Mar 31, 2022
Cytodyn Inc Investment Community Webcast Transcript
Mar 08, 2021
Cytodyn Inc with Dr.Pourhassan gives an update on CytoDyn's COVID-19 path and more on Proactive Transcript
Oct 24, 2020
Cytodyn Inc Investor Call Transcript
Sep 02, 2020
Cytodyn Inc To Host Investment Community Conference Call Transcript
Aug 12, 2020
Cytodyn Inc Dr. Nader Pourhassan, CytoDyn's CEO, Addresses The False Claims Made By STAT News Transcript
Jul 31, 2020
Cytodyn Inc Special Meeting Transcript
Jul 29, 2020
Cytodyn Inc InvestTalk Transcript
Jul 24, 2020
Cytodyn Inc Dr. Pourhassan Discusses Citron Research's False Report Transcript
Jul 02, 2020
Cytodyn Inc Developing New Therapies for Treatment of Human Immunodeficiency Virus Transcript
Jun 18, 2020
Cytodyn Inc To Host Investment Community Conference Call Transcript
Jun 13, 2020
Cytodyn Inc To Host Investor Community Conference Call Transcript
Jun 11, 2020
Cytodyn Inc Discussion on Company's Trials and COVID19 on Crush the Street Call Transcript
Jun 07, 2020
Cytodyn Inc at CytoDyn (OTC: CYDY) June 2 2020 - Livestream Transcript
Jun 02, 2020
Cytodyn Inc Investor Community Conference Call Transcript
May 26, 2020
Cytodyn Inc CytoDyn on Wall Street Reporter with Drs. Pourhassan, Lalezari, and Patterson Transcript
May 21, 2020
Cytodyn Inc at Lee Kelso discusses Leronlimab on WOWO radio Transcript
May 20, 2020
Cytodyn Inc Shares Manuscript Of Potential Coronavirus Treatment Transcript
May 07, 2020
Cytodyn Inc Leronlimab For COVID-19 Coronavirus Treatment Transcript
May 02, 2020
Cytodyn Inc Wall Street Reporter Transcript
May 01, 2020
Cytodyn Inc At This Drug is Now a Leading Contender to Treat COVID-19 Transcript
Apr 27, 2020
Cytodyn Inc COVID-19 Coronavirus Treatment Clinical Data Update Transcript
Apr 18, 2020
Cytodyn Inc Plans on Moving Forward With COVID-19 Trial Transcript
Apr 13, 2020
Cytodyn Inc at CytoDyn (OTC: CYDY) Coronaovirus Treatment gets FDA EMERGENCY IND + update on HIV & Cancer pipeline Transcript
Mar 02, 2020
Cytodyn Inc at This Week on RedChip TV: 3 Stocks Positioned for Upside in 2020 Transcript
Feb 19, 2020
Cytodyn Inc at Cytodyn Inc Next Super Stock Live Hosted by Wall Street Reporter Transcript
Feb 11, 2020
Cytodyn Inc Discusses New HIV Drug and Plans for Commercialization, Addressing $2 Billion Market Call Transcript
Feb 10, 2020
Cytodyn Inc at Cytodyn Inc Next Super Stock Live Hosted by Wall Street Reporter Transcript
Jan 23, 2020

Cytodyn Inc To Provide a Company Update Transcript

Apr 11, 2023 / 08:00PM GMT

Release Date Price: $0.31 (-6.09%)

Transcript 10-Q

Operator

Hello, and welcome to the CytoDyn Investment Community webcast. (Operator Instructions) As a reminder, this conference is being recorded. It is now my pleasure to turn the call over to Cristina De Leon. Please go ahead.

Cristina De Leon

CytoDyn Inc. - IR

Hello, everyone, and thank you for joining us today. This is Cristina De Leon with CytoDyn. Joining us on today's webcast is our President, Cyrus Arman; our CFO, Antonio Migliarese; and our newly appointed Head of Research and Basic Science, Scott Hansen.

Before we begin, it is essential that we provide you with important cautionary language related to certain federal securities laws. Our remarks during today's webcast will include forward-looking statements. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors that are difficult to predict.

Actual results may be materially different from any future results expressed or implied by such forward-looking statements. These risks and uncertainties include, among

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.